15th February 2013
U.S. FDA Approval of Lombard's Aorfix
MVM portfolio company Lombard Medical Technology announces the US Food and Drug Administration ("FDA")approves its stent graft, Aorfix.
Read this article
15th January 2013
Heptares announces deal with Cubist
Heptares Therapeutics has announced that it has signed an agreement with Cubist Pharmaceuticals, Inc (Nasdaq: CBST) to collaborate on the research and discovery of new medicines targeting G protein-coupled receptors (GPCRs).
Read this article
3rd January 2013
eZono AG announces completion of $10m financing led by MVM
MVM Life Science Partners leads investment into portable tablet ultrasound platform and
novel needle guidance technology.
Read this article
22nd November 2012
Dr Bali Muralidhar Joins MVM Life Science Partners
Dr Muralidhar Joins MVM Life Science Partners' London office
Read this article
22nd October 2012
Dr Roger M. Perlmutter Joins Heptares’ Board of Directors
Welwyn Garden City, UK and Boston, MA, USA, 22 October 2012 – Heptares Therapeutics, the leading GPCR drug discovery company, has elected Dr Roger M. Perlmutter, the former Executive Vice President, Research and Development, at Amgen Inc. to its Board of Directors as a Non-executive Director.
Read this article
News Archive
Last 5 Articles | Next 5 Articles
16th October 2007Evotec Reports Positive Top-Line Results in Phase II Study with EVT 201 in Elderly Insomniacs with Daytime Sleepiness
Evotec AG has announced positive top-line results from its second phase II trial of EVT 201 in 149 elderly primary insomnia patients with daytime sleepiness.
The study showed a highly significant improvement between both doses of EVT 201 and placebo on the primary endpoint of polysomnography (PSG) derived Total Sleep Time (TST).
Compared to placebo, mean TST increased by 30.9 minutes (9%) on EVT 201 1.5 mg and 56.4 minutes (17%) on EVT 201 2.5 mg; p=0.0001 and p=<0.0001 respectively.
Significant improvements were also seen across key PSG-derived secondary endpoints including Wake After Sleep Onset (WASO) and Latency to Persistent Sleep (LPS).
Although the study was not powered to show this, the 2.5 mg dose also showed a significant effect on TWT (Total Wake Time) during the second half of the night, indicating that EVT 201 is highly effective in maintaining sleep throughout the night.
| Associated Links Visit Evotec AG |
Downloads Full Press Release |